CN102595904B - 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 - Google Patents

用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 Download PDF

Info

Publication number
CN102595904B
CN102595904B CN201080050000.2A CN201080050000A CN102595904B CN 102595904 B CN102595904 B CN 102595904B CN 201080050000 A CN201080050000 A CN 201080050000A CN 102595904 B CN102595904 B CN 102595904B
Authority
CN
China
Prior art keywords
amino
triazole
cto
cai
orotate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080050000.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102595904A (zh
Inventor
R.A.卡玛丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43648255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102595904(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Priority to CN201510116934.6A priority Critical patent/CN104817507A/zh
Publication of CN102595904A publication Critical patent/CN102595904A/zh
Application granted granted Critical
Publication of CN102595904B publication Critical patent/CN102595904B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080050000.2A 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 Active CN102595904B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510116934.6A CN104817507A (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58444809A 2009-09-04 2009-09-04
US12/584,448 2009-09-04
US12/807,415 2010-09-03
US12/807,415 US8377973B2 (en) 2009-09-04 2010-09-03 Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
PCT/US2010/002430 WO2011028288A1 (en) 2009-09-04 2010-09-03 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510116934.6A Division CN104817507A (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Publications (2)

Publication Number Publication Date
CN102595904A CN102595904A (zh) 2012-07-18
CN102595904B true CN102595904B (zh) 2016-08-03

Family

ID=43648255

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080050000.2A Active CN102595904B (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
CN201510116934.6A Pending CN104817507A (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510116934.6A Pending CN104817507A (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Country Status (19)

Country Link
US (1) US8377973B2 (enExample)
EP (2) EP2963023B1 (enExample)
JP (4) JP2013503861A (enExample)
KR (1) KR101597338B1 (enExample)
CN (2) CN102595904B (enExample)
AP (1) AP3345A (enExample)
AU (1) AU2010290049B2 (enExample)
BR (1) BR112012004539A2 (enExample)
CA (1) CA2772075C (enExample)
CL (1) CL2012000582A1 (enExample)
HK (1) HK1212983A1 (enExample)
IL (1) IL218430A0 (enExample)
MX (2) MX2012002730A (enExample)
MY (1) MY159430A (enExample)
NZ (2) NZ598482A (enExample)
PH (1) PH12015502088A1 (enExample)
RU (1) RU2594155C2 (enExample)
SG (1) SG178413A1 (enExample)
WO (1) WO2011028288A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
KR102623581B1 (ko) * 2016-07-18 2024-01-11 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물
CN112083109B (zh) * 2019-07-08 2021-05-25 广东银珠医药科技有限公司 羧胺三唑杂质及其制备方法和检测方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
CN112358451B (zh) * 2021-01-11 2021-04-13 广东银珠医药科技有限公司 羧胺三唑的合成方法
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN113620892B (zh) * 2021-10-12 2022-02-22 广东银珠医药科技有限公司 羧胺三唑单晶、制备方法及其组合物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304221A2 (en) * 1987-08-20 1989-02-22 Merck & Co. Inc. 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
CN101141879A (zh) * 2005-02-22 2008-03-12 赛威制药公司 提高药物口服生物利用度的方法和低毒性乳清酸盐组合物
CN101273988A (zh) * 1995-07-21 2008-10-01 巧妙疗法股份有限公司 用氨基咪唑甲酰胺和5-氨基或取代的氨基1,2,3-三唑的盐治疗和预防肿瘤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2415740C2 (de) * 1974-04-01 1983-12-01 Servomed Arznei GmbH & Co Pharma KG, 8000 München Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
JPH0356417A (ja) * 1989-05-08 1991-03-12 Merck & Co Inc 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
WO1997003668A1 (en) * 1995-07-21 1997-02-06 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
MXPA06013540A (es) * 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
MX2010002938A (es) * 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
US20150323994A1 (en) * 2014-05-07 2015-11-12 Immersion Corporation Dynamic haptic effect modification
JP2017150532A (ja) * 2016-02-23 2017-08-31 Ntn株式会社 回転伝達装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304221A2 (en) * 1987-08-20 1989-02-22 Merck & Co. Inc. 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
CN101273988A (zh) * 1995-07-21 2008-10-01 巧妙疗法股份有限公司 用氨基咪唑甲酰胺和5-氨基或取代的氨基1,2,3-三唑的盐治疗和预防肿瘤
CN101141879A (zh) * 2005-02-22 2008-03-12 赛威制药公司 提高药物口服生物利用度的方法和低毒性乳清酸盐组合物

Also Published As

Publication number Publication date
EP2963023B1 (en) 2018-04-18
BR112012004539A2 (pt) 2020-09-15
NZ624636A (en) 2014-06-27
US20110060142A1 (en) 2011-03-10
CA2772075C (en) 2017-02-28
NZ598482A (en) 2014-05-30
EP2473051A1 (en) 2012-07-11
JP2020105178A (ja) 2020-07-09
EP2473051A4 (en) 2013-03-13
AP2012006187A0 (en) 2012-04-30
WO2011028288A1 (en) 2011-03-10
JP2017203038A (ja) 2017-11-16
IL218430A0 (en) 2012-04-30
RU2012111454A (ru) 2013-10-10
HK1212983A1 (zh) 2016-06-24
KR101597338B1 (ko) 2016-02-24
MX355198B (es) 2018-04-06
MY159430A (en) 2017-01-13
JP2013503861A (ja) 2013-02-04
CN104817507A (zh) 2015-08-05
PH12015502088B1 (en) 2017-03-22
AP3345A (en) 2015-07-31
AU2010290049B2 (en) 2013-09-19
CA2772075A1 (en) 2011-03-10
PH12015502088A1 (en) 2017-03-22
AU2010290049A1 (en) 2012-03-29
KR20120092587A (ko) 2012-08-21
CN102595904A (zh) 2012-07-18
US8377973B2 (en) 2013-02-19
EP2473051B1 (en) 2016-02-10
MX2012002730A (es) 2012-07-20
CL2012000582A1 (es) 2012-09-07
JP2016026213A (ja) 2016-02-12
EP2963023A1 (en) 2016-01-06
SG178413A1 (en) 2012-03-29
RU2594155C2 (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
CN102595904B (zh) 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
US20060189682A1 (en) Water soluble prodrugs of COX-2 inhibitors
EP2746251A2 (en) Positively charged water-soluble prodrugs of acetaminophen and related compunds with very fast skin penetration rate
EP3210964A1 (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
CN104016951B (zh) 靶向癌症干细胞的化合物和组合物
WO2021114864A1 (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
US20240382511A1 (en) Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
US20040043952A1 (en) Multifunctional polyamines for delivery of biologically-active polynucleotides
US8912223B2 (en) Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
US20250073249A1 (en) Steroid compound, and preparation method therefor and use thereof
US20240317764A1 (en) Salts and solid forms of a compound having apj receptor activity
US20210380558A1 (en) Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
HK1170631B (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
ES2845639T3 (es) Forma cristalina de 6-[(4R)-4-metil-1,2-dióxido-1,2,6-tiadiazinan-2-il]isoquinolin-1-carbonitrilo
HK1170631A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
HK1214824A1 (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
HK1214824B (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
CN103772374B (zh) 一种杂环类化合物及其应用
CN121039145A (zh) 具有可降解头部的可电离脂质
JP2003514803A (ja) 結直腸ガンの発達を防止するための４−（４’−ヒドロキシフェニル）アミノ−６，７−ジメトキシキナゾリン
HK1237331A (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
HK1237331A1 (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1170631

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1170631

Country of ref document: HK